

Ref. No.: LASA/SE/23-24/38
Tuesday, February 13, 2024

To, Corporate Services Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001. BSE CODE –540702	To, Corporate Services Department National Stock Exchange of India Limited “Exchange Plaza”, Plot No. C/1, G Block Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051. NSE CODE: LASA
--	--

Dear Sir/Madam,

Sub. : **Outcome of Board Meeting held today i.e. February 13, 2024**

Pursuant to Regulation 29 and 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today which was commenced at 4.00 p.m. and concluded at 6.15 p.m. inter- alia have considered and approved the following:

1. The statement of unaudited Financial Results of the Company for the quarter ended on December 31, 2023.
2. Limited Review Report from Statutory Auditor for the quarter ended on December 31, 2023.

The above information is also available on the company’s website at www.lasalabs.com and on the website of the stock Exchange at www.bseindia.com and www.nseindia.com.

FOR LASA SUPERGENERICS LIMITED

MITTI JAIN
COMPANY SECRETARY & COMPLIANCE OFFICER
M. NO.33681



LASA SUPERGENERICS LIMITED

Statement of unaudited Financial Results for Quarter and Nine Month ended 31st Dec, 2023

(Rs In Lakhs)

Particulars	Quarter ended			Nine Months Ended		Year ended
	31.12.2023 (Unaudited)	30.09.2023 (Unaudited)	31.12.2022 (Unaudited)	31.12.2023 (Unaudited)	31.12.2022 (Unaudited)	31.03.2023 (Audited)
1. INCOME						
a. Revenue from Operations	2,666.01	2,430.26	3,170.49	8,151.87	9,424.49	12,956.78
b. Other Income	0.36	8.40	86.05	9.14	87.32	180.46
Total Income	2,666.37	2,438.66	3,256.54	8,161.01	9,511.81	13,137.24
2. Expenses						
a. Cost of Materials consumed	1,838.68	1,965.38	2,912.10	6,024.53	8,626.48	11,012.14
b. Cost of Traded Goods	-	-	-	-	-	-
c. Change in Inventories of Finished Goods, Work-in-Progress	154.04	(314.44)	(358.35)	(350.35)	(550.58)	(400.71)
d. Employee benefits expenses	155.49	158.59	180.30	483.35	591.11	736.81
e. Finance costs	44.10	55.76	42.88	137.17	374.58	416.05
f. Depreciation & amortizations expenses	267.96	268.15	308.83	801.14	924.91	1,341.90
g. Other Expenses	412.52	516.40	682.94	1,379.69	1,850.79	2,267.90
Total Expenses (a to g)	2,872.78	2,649.83	3,768.70	8,475.52	11,817.29	15,374.09
Exceptional Items	-	-	-	-	-	1,989.66
3. Profit / (Loss) before tax (1-2)	(206.41)	(211.17)	(512.16)	(314.50)	(2,305.49)	(4,226.51)
4. Tax expense						
Current Tax	-	-	-	-	51.10	(368.77)
Deferred Tax	(60.59)	(208.89)	(20.31)	328.55	-	4.33
Short / Excess income tax provision for earlier years	-	-	-	-	4.33	-
5. Net Profit / (Loss) after tax (3-4)	(145.82)	(2.28)	(491.85)	(643.05)	(2,360.92)	(3,862.07)
6. Other Comprehensive Income						
Items that will not be reclassified into Profit or Loss	-	-	-	-	-	3.91
- Remeasurement of Defined Benefit Plans (Net of tax)	-	-	-	-	-	-
7. Total Comprehensive Income for the year (after tax) (5+6)	(145.82)	(2.28)	(491.85)	(643.05)	(2,360.92)	(3,858.16)
8. Paid-up Equity Share Capital (Face Value of Rs. 10/- each)	5,010.12	5,010.12	4,067.27	5,010.12	4,067.27	5,010.12
9. Other Equity excluding Revaluation reserve as per Balance Sheet						
10. Earnings per Equity Share (of Rs. 10/- each)						
(a) Basic	(0.29)	(0.00)	(1.21)	(1.28)	(5.80)	(7.71)
(b) Diluted	(0.29)	(0.00)	(1.21)	(1.28)	(5.80)	(7.71)

Notes :

1) "These interim condensed financial statements are prepared in accordance with Indian Accounting Standard (Ind AS) 34 Interim Financial Reporting, under the historical cost convention on accrual basis except for certain financial instruments which are measured at fair values, the provisions of the Companies Act, 2013 ("the Act") (to the extent notified) and guidelines issued by the Securities and Exchange Board of India (SEBI). Accordingly, these interim condensed financial statements do not include all the information required for a complete set of financial statements. These interim condensed financial statements should be read in conjunction with the financial statements and related notes included in the Company's Annual Report for the year ended March 31, 2023. The Ind AS are prescribed under Section 133 of the Act read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and relevant amendment rules issued thereafter."

2) The Above Financial Results were reviewed by the audit committee of the board on 13 February 2024 and approved by the Board of Directors of the company at their meeting held on same date. The Statutory auditors have expressed on unmodified opinion. The auditors report has been filed with stock exchange and is available on the company's website. The Financial results have been prepared in accordance with Ind AS notified under the Companies (Accounting Standards) Rule, 2015.

3) Finance Cost for YTD Dec23, includes ECB interest Rs. 1,25,88,384 provision for interest on alleged ECB Loan (Which is Disputed) as per IND AS.


4) The Company has paid advances Rs.470 Lakhs to Arch Herbals Pvt Ltd in the Financial Year 2020 and 2021 on behalf of Omkar Speciality Chemicals Ltd against which material was supposed to be supplied by OSCL, in the meantime OSCL admitted into CIRP, Company have filed claim with Resolution Professional status of which is still under inspection. The said advance is forming part of Note 12 - Other Current Assets- Advance paid to Suppliers.

5) The Company has single business segment i.e. Active Pharmaceutical Ingredients (API), therefore, in the context of Ind As 108, disclosure of segment information is not applicable.

6) Figures of previous period have been re-grouped / reclassified wherever necessary, to confirm to this period's classification.

For Lasa Supergenics Ltd


Omkar Herlekar
Chairman & Managing Director
(DIN No. 01587154)



Place : Mumbai
Date : 13th February, 2024

Factory & Regd. Office: - C-4, C-4/1, M.I.D.C. LOTE PARSHURAM INDUSTRIAL AREA, TAL-KHED, DIST-RATNAGIRI 415722.

CIN: L24233MH2015PLC274202 Email: info@lasalabs.com Website: www.lasalabs.com

Independent Auditor's Limited Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To

The Board of Directors of

Lasa Supergenerics Ltd

1. We have reviewed the accompanying statement of unaudited standalone financial results (The "Statement") of **Lasa Supergenerics Ltd** ('the Company') for the quarter ended December 31, 2023 and year to date from April 01, 2023 to December 31, 2023 attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 and 52 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations")
2. The statement which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of Material misstatement. A review is limited primarily to inquiry of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. As mentioned in Note 4 of the Statement wherein the Company has mentioned has paid advances Rs.470 Lakhs to Arch Herbals Pvt Ltd in the Financial Year 2020 and 2021 on




behalf of Omkar Speciality Chemicals Ltd (OSCL) against which material was supposed to be supplied by OSCL, in the meantime OSCL was admitted into CIRP on 20.12.2022, Company have filed claim with Resolution Professional status of which is still under inspection. The said advance is forming part of Other Current Assets- Advance paid to Suppliers. As mentioned in Note 4 of the accompanying statement of unaudited standalone financial results the Company has continued to carry this advance at book value. The impact of the same on the standalone financial statement of the Company is unascertainable at this stage.

5. Emphasis of Matter

The company does not have insurance cover for any of its assets. We are informed that company had disputed the insurance settlement amount offered by the insurance company against the claim filed by the company (flood insurance claim pertaining to 2019-20). The company should take immediate steps to resolve the issue and obtain necessary insurance cover to avoid any contingencies for which no provision has been made.

6. Based on our review conducted as above, *except for the possible effects of our observations in paragraph 4 above*, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with the applicable accounting standard and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulation, 2015 including the manner in which it is to be disclosed , or that it contains any material misstatement.

For **Gupta Rustagi & Co.**
Chartered Accountants
ICAI FRN : 128701W



Niraj Gupta
Partner

M.N.no. 100808

Place: Mumbai

Date: 13th February, 2024

UDIN: 24100808BKDHVA2940

